Physician profile
Francisco Padilla
NPI 1831399310
$22,330.32
in general payments reported to CMS, 2019-2025
53 companies · $16K in 2025
The $16K reported for 2025 was more than what 92% of Endocrinology, Diabetes & Metabolism providers received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,622 · 2020: $363 · 2021: $832 · 2022: $974 · 2023: $1,467 · 2024: $865 · 2025: $16K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $15K · Food and Beverage: $3,676 · Travel and Lodging: $246 · Education: $31.33.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $14,586.00 |
| Food and Beverage | $3,676.32 |
| Travel and Lodging | $245.86 |
| Education | $31.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ascendis Pharma Endocrinology INC | $14,965.76 | 2025 | Yorvipath |
| Novo Nordisk INC | $1,561.53 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Insulet Corporation | $794.96 | 2019-2025 | Omnipod |
| Lilly USA, LLC | $642.48 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Abbott Laboratories | $535.73 | 2019-2025 | Freestyle Libre 3 |
| Sanofi-Aventis U.S. LLC | $450.39 | 2019-2025 | |
| Astrazeneca Pharmaceuticals Lp | $398.15 | 2019-2025 | Farxiga, Airsupra |
| Amgen INC. | $312.76 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $273.07 | 2019-2025 | Jardiance |
| Mallinckrodt Hospital Products INC. | $220.65 | 2022-2024 | Acthar |
| Xeris Pharmaceuticals, INC. | $162.95 | 2021-2025 | Gvoke Hypopen, Recorlev |
| Jazz Pharmaceuticals INC. | $155.04 | 2019-2021 | |
| Corcept Therapeutics | $144.71 | 2019-2023 | Korlym |
| Dexcom, INC. | $136.98 | 2021-2024 | Dexcom G6 Transmitter, Dexcom G7 Gss (161) |
| Bayer Healthcare Pharmaceuticals INC. | $126.22 | 2022-2024 |
Show all 53 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tandem Diabetes Care, INC. | $107.79 | 2019-2024 | T:Slim X2 Insulin Pump With Control-Iq |
| Novartis Pharmaceuticals Corporation | $107.47 | 2022-2023 | |
| Ucb, INC. | $93.28 | 2019-2025 | Rystiggo |
| Akcea Therapeutics, INC. | $86.88 | 2019 | |
| Janssen Pharmaceuticals, INC | $82.69 | 2019-2022 | |
| Valeritas, INC. | $76.29 | 2019 | |
| Mallinckrodt Enterprises LLC | $70.63 | 2019 | |
| Pfizer INC. | $61.34 | 2023-2025 | |
| Alexion Pharmaceuticals, INC. | $56.76 | 2023-2025 | Strensiq, Ultomiris |
| Lundbeck LLC | $51.52 | 2023 | Vyepti |
| Merck Sharp & Dohme LLC | $47.84 | 2025 | Gardasil 9, Capvaxive |
| Cequr Corporation | $43.47 | 2023-2024 | Cequr Simplicity |
| Abbvie INC. | $39.03 | 2019-2020 | |
| Becton, Dickinson and Company | $36.81 | 2019-2021 | |
| Eisai INC. | $36.35 | 2019-2023 | |
| Beta Bionics, INC. | $33.16 | 2024-2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Inset, Ilet Insulin Infusion Kit Contact Detach |
| Radius Health, INC. | $27.86 | 2024 | Tymlos |
| Shire North American Group INC | $26.11 | 2019 | |
| Glaxosmithkline, LLC. | $25.69 | 2023 | Trelegy Ellipta, Arexvy, Shingrix |
| Genentech USA, INC. | $24.95 | 2025 | Ocrevus Zunovo |
| Companion Medical, INC. | $21.49 | 2020 | |
| Idorsia Pharmaceuticals US INC | $21.47 | 2023 | Quviviq |
| Ani Pharmaceuticals, INC. | $21.23 | 2024 | Purified Cortrophin Gel |
| Lifescan, INC. | $20.76 | 2022 | |
| Boston Scientific Corporation | $20.48 | 2025 | General - Dbs |
| Sk Life Science, INC. | $19.65 | 2025 | |
| Recordati_rare_diseases_inc. | $19.04 | 2024 | Signifor Lar, Isturisa |
| Avanir Pharmaceuticals, INC. | $18.98 | 2019 | |
| Grifols USA, LLC | $18.01 | 2023 | Prolastin-C Liquid |
| Verona Pharma, INC. | $16.67 | 2025 | Ohtuvayre |
| Biogen, INC. | $16.18 | 2023 | Tysabri, Vumerity |
| Astellas Pharma US INC | $15.14 | 2019 | |
| Neurelis, INC. | $14.89 | 2023 | Valtoco |
| Sequel Med Tech, LLC | $14.70 | 2025 | Twiist |
| Baxter Healthcare | $14.70 | 2022 | |
| Electromed, INC. | $13.79 | 2024 | Smartvest |
| Ipsen Biopharmaceuticals, INC | $13.47 | 2020 | |
| Ferring Pharmaceuticals INC. | $12.37 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Francisco Padilla listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.